A Win For Salarius Pharmaceuticals, Inc.
Salarius Pharmaceuticals, Inc. (SLRX:NASDAQ) soared at $2.61, a gain of 69.5%. On Tue, Jul 23, 2024, SLRX:NASDAQ touched a New 2-Week Intraday High of $7.2. From Tue, Jul 09, 2024, the stock recorded 30.00% Up Days and 36.36% Green Days
The stock spiked on Tue, Jul 23, 2024 at $7.2 with a volume of 59M+.
About Salarius Pharmaceuticals, Inc. (SLRX:NASDAQ)
Flex Pharma Inc is a US-based biotechnology company which is engaged in the developing proprietary treatments for muscle cramps and spasms associated with severe neurological conditions and exercise-associated muscle cramps. The lead drug product candidate is FLX-787 which is a single molecule, chemically synthesized, TRP ion channel activator and HOTSHOT, which is developed to prevent and treat exercise-associated muscle cramps. It operates through two segments - Consumer Operations and Drug Development. The Consumer Operations segment includes the development of HOTSHOT whereas the Drug Development segment includes the development of proprietary drug products to treat muscle cramps and spasms associated with severe neurological conditions.
Top 10 Gainers:
- Regencell Bioscience Holdings Limited (RGC:NASDAQ), 343.92%
- Azitra Inc (AZTR:NYSEMKT), 206.79%
- Republic First Bancorp, Inc. (FRBK:NASDAQ), 100%
- Tempo Automation Holdings Inc. (TMPO:NASDAQ), 84.62%
- Salarius Pharmaceuticals, Inc. (SLRX:NASDAQ), 69.48%
- Calithera Biosciences, Inc. (CALA:NASDAQ), 60%
- Chijet Motor Company Inc. (CJET:NASDAQ), 55.35%
- Arrowroot Acquisition Corp. (ARRW:NASDAQ), 54.64%
- Agape ATP Corporation (ATPC:NASDAQ), 50.35%
- Golden Sun Education Group Limited (GSUN:NASDAQ), 47.43%